SEARCH

SEARCH BY CITATION

The authors would like to draw the reader's attention to an error in the following article:

Yamasaki C, Uchiyama A, Nakanishi H, Masumoto K, Aoyagi H, Washio Y, Totsu S, Imai K and Kusuda S. Hydrocortisone and long-term outcomes in very-low-birthweight infants. Pediatrics International 2012; 54: 465–470.

On page 468, “Corrected age (weeks)” found in Table 1 should have been 29.9 ± 2.7, as shown below.

Table 1. Background characteristics of the 24 infants treated with hydrocortisone
FactorsNumber of infants or incidence
  1. a

    Type of CLD according to the classification of the Japanese Ministry of Health, Labour and Welfare Study Group. Values presented as means ± standard deviation or number of cases. CLD, chronic lung disease; HFO, High-frequency oscillatory ventilation; Nasal DPAP, Nasal CPAP with infant flow system; RDS, respiratory distress syndrome; TTN, transient tachypnea of newborn.

Sex (M : F)12:12
Respiratory problem at birth
TTN7 (29.2%)
RDS17 (70.8%)
Type of CLDa
I9 (37.5%)
II8 (33.3%)
III4 (16.7%)
IV0
V3 (12.5%)
Hydrocortisone administration
Days after birth21.2 ± 9.7
Corrected age (weeks)29.9 ± 2.7
Bodyweight (g)784 ± 206
Respiratory support
HFO16
Nasal DPAP6
Oxygen cannula2
Initial dose (mg/kg)2.08 ± 0.97
Number of doses
18
210
36
Total dose (mg/kg)4.0 ± 2.6
Additional improvement besides oxygenation
Increase in systolic pressure4 (16.7%)
Improvement in urine output11 (45.8%)
Adverse effects after treatment
Hyperglycemia (fasting blood sugar ≥ 200 mg/dL)6 (25%)
Hypertension (systolic blood pressure ≥ 80 mmHg)2 (8.3%)

The authors apologize for this error and any inconvenience it may have caused.